InsidersTradesSigma
Track the ABIVAX stock price and the full directors' dealings record of the company, a publicly traded company based in France. Shares are listed on the FR market, under the authority of AMF. Operating in the Healthcare & Pharma sector, ABIVAX has recorded 67 public disclosures. Market capitalisation: €8.5bn. The latest transaction was disclosed on 16 July 2026 (Cession). Among the most active insiders: marc de garidel thoron. The full history is accessible without an account.
67
Insider Decl.
n/a
Thresholds
€10m
10 ops.
Buy Volume
€282m
22 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ABIVAX Buy (bullish), based on 6 analysts. Average price target: €138.97.
22Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 July 2026
Declarations67 total
3,375 shares@ €120.86760.0039% mcap100.0% of flowActionEuronext ParisISIN FR00123332842026DD1127138
12,500 shares0ActionEuronext ParisISIN FR00123332842026DD1126730
Canonical exit: 9 Oct 2026 (T+90)
17,728 shares0ActionEuronext ParisISIN FR00123332842026DD1126711
Canonical exit: 9 Oct 2026 (T+90)
17,728 shares0ActionEuronext ParisISIN FR00123332842026DD1123383
Canonical exit: 24 Sept 2026 (T+90)
35,456 shares0ActionEuronext ParisISIN FR00123332842026DD1116477
Canonical exit: 19 Aug 2026 (T+90)
35,456 shares0ActionEuronext ParisISIN FR00123332842026DD1102067
Canonical exit: 17 Jun 2026 (T+90)
2,471 shares@ €20.2350.0% of flowWarrants BSA 2026/1Euronext ParisISIN FR00123332842026DD1095725
7,661 shares@ €20.2375.6% of flowBSA 2026-1Euronext ParisISIN FR00123332842026DD1095418
217,728 shares0ActionEuronext ParisISIN FR00123332842026DD1092212
Canonical exit: 2 May 2026 (T+90)
950,000 shares@ US$122.407939.2% of flowAmerican Depositary SharesNasdaq Global Market (US)ISIN FR00123332842026DD1089198
17,728 shares0ActionEuronext ParisISIN FR00123332842025DD1074474
Canonical exit: 11 Mar 2026 (T+90)
16,400 shares@ €11.5779.1% of flowwarrantsEuronext ParisISIN FR00123332842025DD1072558
35,456 shares0ActionEuronext ParisISIN FR00123332842025DD1070453
Canonical exit: 11 Feb 2026 (T+90)
590,877 shares@ €94.16418.8% of flowAmerican Depositary SharesNasdaq Global MarketISIN FR00123332842025DD1066576
590,877 shares@ US$94.16418.8% of flowAmerican Depositary SharesNasdaq Global MarketISIN FR00123332842025DD1066880
17,728 shares0ActionEuronext ParisISIN FR00123332842025DD1062687
17,728 shares0ActionEuronext ParisISIN FR00123332842025DD1056809
1,104,640 shares@ €15.087921.8% of flowActionEuronext ParisISIN FR00123332842025DD1053421
1,104,640 shares@ €54.0078.2% of flowActionEuronext ParisISIN FR00123332842025DD1053431
17,728 shares0ActionEuronext ParisISIN FR00123332842025DD1051889
270,000 shares@ US$64.005.8% of flowAmerican Depositary SharesNasdaq Global MarketISIN FR00123332842025DD1050946
17,728 shares0ActionEuronext ParisISIN FR00123332842025DD1044615
Canonical exit: 22 Sept 2025 (T+90)
17,728 shares0ActionHors plateforme de négociationISIN FR00123332842025DD1040533
Canonical exit: 26 Aug 2025 (T+90)
39,370 shares@ €1.2750.0% of flowWarrants BSA 2025Euronext ParisISIN FR00123332842025DD1036451
25 of 67 declarations
关于 ABIVAX
Abivax SA是一家法国临床阶段生物技术公司，专注于开发治疗慢性炎症性疾病的创新疗法。该公司于2013年在巴黎成立，通过围绕受人体自然生物学启发的免疫调节机制构建其战略，逐步确立了其作为欧洲知名生物技术公司的地位。自2015年6月26日起，Abivax在泛欧交易所巴黎上市，并自2023年10月起在纳斯达克全球市场交易，使其同时接触欧洲和美国资本市场。其ISIN为FR0012333284。 该公司的业务核心是开发其主要资产obefazimod，这是一种口服的microRNA-124 (miR-124) 调节剂。该候选药物主要用于治疗溃疡性结肠炎，这是一种慢性炎症性肠病，旨在为现有治疗方法未能充分控制的患者提供差异化的治疗选择。Abivax将obefazimod定位为其产品线基石，其3期临床数据发布代表着关键的价值创造催化剂。该公司还强调了一个专有化学库，可能提供额外的长期开发机会。 历史上，Abivax最初围绕免疫学和抗病毒方法建立了其科学平台，随后将重点转向慢性炎症性疾病。这一战略转变反映了管理层将资源集中于具有最高临床和商业潜力的项目的意图。如今，Abivax仍然主要是一家研发公司，其经济模式取决于临床进展、可能的战略合作以及最终获批产品的商业化。 Abivax具有国际影响力，在法国和美国设有活动和团队，以支持临床试验、投资者关系和监管开发。其在2025年12月被纳入纳斯达克生物技术指数，进一步增强了其形象，凸显了在全球生物技术生态系统中的日益增长的认可。作为一家成长阶段的生物技术发行人，Abivax结合了先进科学、显著的临床风险以及如果其主要项目成功进入市场所带来的巨大上行潜力。
